The JAK2 inhibitor fedratinib is an FDA‐approved drug with an indication for myelofibrosis, and the MEK inhibitor trametinib is clinically used to treat various cancers, including malignant melanoma and nonsmall cell lung cancer. Here, MAP2K7 is linked to cancer.